2 / 22
Page 24
conferenceseries
.com
Volume 7, Issue 4 (Suppl)
J Biotechnol Biomater, an open access journal
ISSN: 2155-952X
Bio America 2017
October 19-20, 2017
October 19-20, 2017 | New York, USA
18
th
Biotechnology Congress
Nanobiomedical device system for nanomedicine and innovative business
HeaYeon Lee
1, 2
1
Northeastern University, USA
2
Mara Nanotech New York, Inc., USA
A
newparadigmof nanobiomedical devices has been exploited in areas such as combinational chemistry, biotechnology, engineering
and clinical diagnostics. One of the critical issues in the nanobiomedical system is how to differentiate signal-to-noise (S/N)
ratio per very small amount of signal for high sensitivity homogenous assays. Until now, we achieved high /specific detection of
biomolecule using arrayed nanostructures (i.e., nanowells). The electrochemical (EC) nanowell array biosensors have significantly
improved biomolecular detection by increasing sensitivity, limit of detection (LOD), S/N ratio, multi-targeting, and being label-free,
compared to conventional micro sensors. The nanowell sensors have extremely low volume on the order of atto-liters (10-18 L) per
well, and a total volume of approximately 32 femto-liters per sensor. Due to the geometrical constraints of nanowells, they can be
designed to allow for the immobilization of only a few biomolecules.This leads to significant improvement of sensor sensitivity because
it reduces potential aggregation and enhances the spatial orientation of the biomolecules compared with conventional electrodes with
flat surfaces. Here I'll describe a demonstration of precious molecule recognition while maintaining the bioactivity on nanostructured
space. We performed biosensing within nanowells for the EC detection of stress-induced-phosphoprotein-1 (STIP-1), a biomarker for
ovarian cancer. The sensitivity of the nanowells impedimetric immunosensor was better for each analyte concentration tested when
compared the sensitivity of the bare electrode sensor. The EC nanowell biosensor showed the 10 pg/mL LOD, which had 100-fold
improvement compared with bare microelectrode. The developed miniaturized/integrated nanowell array-device system has shown
excellent advantages over conventional instrumental systems for analysis of biomaterials in its size, cost, detection time and multiplex
detection capability. I'll also present the relationship between particle uptake and distribution for TiO2 nanoparticles (NPs) and
cosmeceutical-NPs modified with fatty acied (palmitoleic acid, palmitic acid, stearic acid, and oleic acids) in human fibroblast skin
and adenocarcinoma lung cells for chemotherapy. Finally, I'll describe the plan to commercialize nanomedical device system for Fast,
Easy-to-use, Accurate, and Low-cost (FEAL) personalized healthcare.
Biography
HeaYeon Lee, PhD, is President and CEO of Mara Nanotech New York, Inc., USA and a Visiting Professor at the Department of Pharmaceutical Sciences, Bouve College
of Health Sciences, Northeastern University, Boston, MA. She received her BS (1987) and MS degrees (1990) in Chemistry from Pukyong National University, South Korea
and her PhD degree (1995) in Chemistry from Osaka University, Japan. After finishing advanced degrees in nanofabrication and characterization technologies, she has
been working on developing new nanobioelectronic devices and nanobiosensors. She was a Designated Professor at the Institute of Scientific and Industrial Research,
Osaka University, and Research Associate Professor of Mechanical and Industrial Engineering at Northeastern University, Boston, USA. Her research work has been con-
tributing to accelerating cutting-edge research in the emerging bio-nanoscience area.
he.lee@northeastern.eduHeaYeon Lee, J Biotechnol Biomater 2017, 7:4 (Suppl)
DOI: 10.4172/2155-952X-C1-079